Rubius Therapeutics (NASDAQ:RUBY) Price Target Cut to $15.00

Rubius Therapeutics (NASDAQ:RUBYGet Rating) had its target price decreased by HC Wainwright from $40.00 to $15.00 in a report issued on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock.

Several other equities analysts have also weighed in on RUBY. SVB Leerink dropped their price objective on shares of Rubius Therapeutics from $14.00 to $5.00 and set a market perform rating on the stock in a report on Friday, February 25th. Guggenheim cut their price target on Rubius Therapeutics from $32.00 to $25.00 in a report on Monday, January 3rd. Finally, Zacks Investment Research downgraded Rubius Therapeutics from a hold rating to a sell rating in a report on Tuesday, February 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of Hold and an average target price of $7.60.

RUBY opened at $2.41 on Monday. Rubius Therapeutics has a twelve month low of $2.33 and a twelve month high of $29.94. The company has a fifty day moving average of $5.28 and a 200-day moving average of $10.08. The stock has a market cap of $217.35 million, a PE ratio of -1.08 and a beta of 2.48. The company has a quick ratio of 6.63, a current ratio of 6.63 and a debt-to-equity ratio of 0.43.

Rubius Therapeutics (NASDAQ:RUBYGet Rating) last issued its quarterly earnings results on Friday, February 25th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.03). During the same quarter in the previous year, the business earned ($0.50) earnings per share. Sell-side analysts anticipate that Rubius Therapeutics will post -2.28 EPS for the current fiscal year.

In other news, CEO Pablo J. Cagnoni sold 6,730 shares of the stock in a transaction that occurred on Tuesday, February 1st. The stock was sold at an average price of $6.57, for a total value of $44,216.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 55.70% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in shares of Rubius Therapeutics by 1.4% in the third quarter. BlackRock Inc. now owns 3,484,480 shares of the company’s stock valued at $62,302,000 after purchasing an additional 48,645 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Rubius Therapeutics during the 3rd quarter worth approximately $189,000. Renaissance Technologies LLC purchased a new position in shares of Rubius Therapeutics in the 3rd quarter worth approximately $367,000. Bellwether Advisors LLC bought a new position in shares of Rubius Therapeutics in the third quarter valued at approximately $525,000. Finally, Baillie Gifford & Co. increased its position in shares of Rubius Therapeutics by 5.0% during the fourth quarter. Baillie Gifford & Co. now owns 4,930,859 shares of the company’s stock valued at $47,730,000 after acquiring an additional 237,027 shares during the last quarter. 96.94% of the stock is currently owned by hedge funds and other institutional investors.

Rubius Therapeutics Company Profile (Get Rating)

Rubius Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.

Further Reading

The Fly logo

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.